Owkin has expanded its collaboration with pharmaceutical company Servier through a new agreement providing access to K Pro, Owkin's agentic AI scientist, alongside multimodal patient data. The partnership will support Servier's oncology research, particularly its efforts to better understand the biology of hard-to-treat cancers and accelerate the discovery and development of new therapies.
Under the agreement, Servier's research teams will be able to analyze multimodal patient data from Owkin's MOSAIC network directly through K Pro. By combining clinical and biological patient information with specialized AI capabilities in a single environment, the companies aim to help researchers generate, investigate and validate hypotheses more efficiently than through conventional manual analysis.
K Pro is designed as an AI scientist supporting multiple stages of pharmaceutical research and development. The platform combines agentic AI with specialized biological tools to assist with target discovery, molecule optimization, biomarker identification, patient subgroup selection and clinical trial design. Owkin says the system incorporates knowledge developed through a decade of pharmaceutical partnerships and is trained and validated using real-world patient data and experimental research from its wet lab.
The agreement builds on previous work between Owkin and Servier focused on identifying patient subgroups in oncology. The expanded relationship moves beyond individual research projects by giving Servier scientists direct access to Owkin's AI and patient data infrastructure, potentially allowing the technology to support a broader range of oncology research programs.
The collaboration reflects growing pharmaceutical interest in agentic AI systems capable of supporting scientists across the drug development lifecycle. By pairing multimodal patient datasets with autonomous biological analysis, Owkin and Servier aim to accelerate research decisions and identify new therapeutic opportunities for cancers where treatment options remain limited.
Click here to read the original news story.
